AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Interleukin-7 receptor subunit alpha

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

Our high-tech, dedicated method is applied to construct targeted libraries for receptors.

 Fig. 1. The sreening workflow of Receptor.AI

This process includes extensive molecular simulations of the receptor in its native membrane environment, along with ensemble virtual screening that accounts for its conformational mobility. In the case of dimeric or oligomeric receptors, the entire functional complex is modelled, identifying potential binding pockets on and between the subunits to encompass all possible mechanisms of action.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

P16871

UPID:

IL7RA_HUMAN

Alternative names:

CDw127

Alternative UPACC:

P16871; B2RCS6; B4DVT1; Q05CU8; Q6NSP4; Q6NWM0; Q6NWM1; Q6NWM2; Q6NWM3; Q6SV45; Q9UPC1

Background:

Interleukin-7 receptor subunit alpha (IL-7Rα), also known as CDw127, plays a pivotal role in the immune system by acting as a receptor for interleukin-7 and thymic stromal lymphopoietin (TSLP). These interactions are crucial for the development and function of T cells and B cells, highlighting its significance in maintaining immune homeostasis.

Therapeutic significance:

IL-7Rα's involvement in Immunodeficiency 104 and Multiple Sclerosis 3 underscores its therapeutic potential. For Immunodeficiency 104, characterized by severe immune dysfunction, targeting IL-7Rα could enhance immune responses. In Multiple Sclerosis 3, modulating IL-7Rα activity might offer a novel approach to mitigate autoimmune attacks on the central nervous system. Understanding the role of IL-7Rα could open doors to potential therapeutic strategies.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.